These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34813073)

  • 21. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
    Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nirsevimab: Alleviating the burden of RSV morbidity in young children.
    Loe MWC; Soenong H; Lee E; Li-Kim-Moy J; Williams PC; Yeo KT
    J Paediatr Child Health; 2024 Oct; 60(10):489-498. PubMed ID: 39150043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
    Coma E; Martinez-Marcos M; Hermosilla E; Mendioroz J; Reñé A; Fina F; Perramon-Malavez A; Prats C; Cereza G; Ciruela P; Pineda V; Antón A; Ricós-Furió G; Soriano-Arandes A; Cabezas C
    Arch Dis Child; 2024 Aug; 109(9):736-741. PubMed ID: 38857952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: First results in a tertiary hospital in Madrid.
    Molina Gutiérrez MÁ; de Miguel Lavisier B; Ruiz Domínguez JA; García de Oteyza M; Velasco Molina VM; Gutiérrez Arroyo A; de Ceano-Vivas M
    Enferm Infecc Microbiol Clin (Engl Ed); 2024; 42(7):367-372. PubMed ID: 39013707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care.
    Alejandre C; Penela-Sánchez D; Alsina J; Agüera M; Soler A; Moussalam S; Muñoz-Almagro C; Brotons P; Cambra FJ; Forner OR; Balaguer M; Launes C; Jordan I
    Eur J Pediatr; 2024 Sep; 183(9):3897-3904. PubMed ID: 38910199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.
    Mankad VS; Leach A; Chang Y; Wählby Hamrén U; Kiazand A; Kubiak RJ; Takas T; Villafana T; Shroff M
    Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
    Agüera M; Soler-Garcia A; Alejandre C; Moussalam-Merino S; Sala-Castellví P; Pons G; Penela-Sánchez D; González-Grado C; Alsina-Rossell J; Climent C; Esteva C; Fortuny C; de-Sevilla MF; García-García JJ; Brotons P; Balaguer A; Estrada J; Jordan I; Muñoz-Almagro C; Launes C
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14175. PubMed ID: 38899631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain.
    Pérez Martín JJ; Zornoza Moreno M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2365804. PubMed ID: 39137331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Wilkins D; Langedijk AC; Lebbink RJ; Morehouse C; Abram ME; Ahani B; Aksyuk AA; Baraldi E; Brady T; Chen AT; Chi H; Choi EH; Cohen R; Danilenko DM; Gopalakrishnan V; Greenough A; Heikkinen T; Hosoya M; Keller C; Kelly EJ; Kragten-Tabatabaie L; Martinón-Torres F; de Los Santos AHM; Nunes MC; Palomino MA; Papenburg J; Pernica JM; Richmond P; Stein RT; Tuffy KM; Verwey C; Esser MT; Tabor DE; Bont LJ;
    Lancet Infect Dis; 2023 Jul; 23(7):856-866. PubMed ID: 36940703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nirsevimab: First Approval.
    Keam SJ
    Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.
    López-Lacort M; Corberán-Vallet A; Santonja FJ; Muñoz-Quiles C; Díez-Domingo J; Orrico-Sánchez A
    J Infect Public Health; 2024 Aug; 17(8):102492. PubMed ID: 39002465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
    Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT
    Nat Med; 2023 May; 29(5):1172-1179. PubMed ID: 37095249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.